Silence Therapeutics is a biotechnology company focused on the discovery, development, and delivery of novel RNA therapeutics for diseases with significant unmet medical needs. The company specializes in the development of RNA interference (RNAi) technology to create new generation medicines.

Silence Therapeutics

Angel style VC focused on climate tech 
- Check size: $100 to $700k
- Models: SaaS, HaaS and marketplaces
- Verticals: Energy, proptech and circularity
- Global: Europe, US and Latam




Silence

Proud to partner up with the BlueLayer team in their mission to transform the carbon credits market. They're building an operating system to provide carbon project developers with end to end support. The potential is infinite! 

Metric
Company Name	Silence Therapeutics
Symbol
MSH ID	COM:SILENCEVC
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country
Stage
Employee Count	5
Website	silencevc.com
LinkedIn	silencevc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	16.81
28-Day Growth Score	22.84
90-Day Growth Score	20.53
365-Day Growth Score	71.64

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SILENCEVC

Silence Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue